Prioritizing Clinical Research on Bacteriophage Therapy
Author Information
Author(s): Santini Joanne M, Edwards Sarah J.L., Tao Yiran, Elias Rodas, Schooley Robert
Primary Institution: University College London
Hypothesis
How should research priorities be set for bacteriophage therapy in the context of antimicrobial resistance?
Conclusion
Bacteriophage therapy presents a promising alternative to antibiotics, but a coordinated effort is needed to overcome regulatory and research barriers.
Supporting Evidence
- AMR is responsible for approximately 1.2 million deaths annually.
- Bacteriophages could be a solution for drug-resistant pathogens.
- The traditional DALY metric has not been effectively applied to AMR globally.
- Unique features of bacteriophages complicate standard research methodologies.
- A coordinated effort among researchers, clinicians, and regulators is essential.
Takeaway
Bacteriophages are viruses that can kill bacteria and might help treat infections that antibiotics can't. We need to figure out how to study them better to help people.
Potential Biases
Potential biases in prioritization methods may overlook the needs of low-income countries.
Limitations
Current research lacks standardized reporting and there is no consensus on the best methods for prioritizing bacteriophage research.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website